PH 15

Drug Profile

PH 15

Alternative Names: PH15; PH15 NS

Latest Information Update: 23 Dec 2015

Price : $50

At a glance

  • Originator Pherin Pharmaceuticals
  • Class Nootropics
  • Mechanism of Action Chemoreceptor cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cognition disorders

Most Recent Events

  • 23 Dec 2015 Phase-I clinical trials in Cognition disorders in USA (Intranasal)
  • 05 Oct 2015 Preclinical development is ongoing in USA
  • 17 Jan 2011 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top